8-丙-2-炔氧基-1-氮杂双环[2.2.2]辛烷马来酸盐 | 147025-54-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 8-丙-2-炔氧基-1-氮杂双环[2.2.2]辛烷马来酸盐
• 英文名称: Talsaclidine fumarate
• 英文别名: (E)-but-2-enedioic acid;(3R)-3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
• CAS: 147025-54-5
• 化学式: C14H19NO5
• 分子量: 281.3
• InChiKey: SBCXBWBXWKVIFK-PBBCPHEYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.44
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(2-propynyloxy)-1-azabicyclo[2,2,2]octane 生成 8-丙-2-炔氧基-1-氮杂双环[2.2.2]辛烷马来酸盐
  参考文献：
  名称：

  Quinuclidines, their use as medicaments and processes for their

  摘要：

  本发明涉及新的喹诺啡啶，以及制备它们的过程和它们作为具有胆碱样作用的药物的用途。

  公开号：

  US05286864A1

文献信息

• Quinuclidines, their use as medicaments and processes for their
  申请人：Boehringer Ingelheim KG

  公开号：US05286864A1

  公开（公告）日：1994-02-15

  The invention relates to new quinuclidines, processes for their preparation and their use as medicaments having cholinomimetic properties.

  本发明涉及新的喹诺啡啶，以及制备它们的过程和它们作为具有胆碱样作用的药物的用途。
• ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT
  申请人：JPV01 Ltd

  公开号：EP4026898A1

  公开（公告）日：2022-07-13

  The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogenic platelets.

  本发明提供了具有所需靶向特异性嵌合血小板受体（CPR）的工程血小板。此外，人造血小板可包含货物，货物可在血小板活化时释放。此外，血小板可由巨核细胞在体外生成，以产生不凝血的血小板。
• Engineered platelets for targeted delivery of a therapeutic agent
  申请人：JPV01 LTD.

  公开号：US11518796B2

  公开（公告）日：2022-12-06

  The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated in vitro from megakaryocytes engineered to generate non-thrombogemc platelets.

  本发明提供了具有所需靶向特异性嵌合血小板受体（CPR）的工程血小板。此外，人造血小板可包含货物，货物可在血小板活化时释放。此外，血小板可由巨核细胞体外生成，以产生非血栓性血小板。
• Medical formulation containing a muscarinic agonist
  申请人：——

  公开号：US20020160048A1

  公开（公告）日：2002-10-31

  A film-coated tablet containing talsaclidine comprising: (a) a core comprising talsaclidine or a physiologically acceptable acid addition salt thereof; and (b) a film coating, wherein the film coating envelops the core.

  一种含他沙西啶的薄膜包衣片剂，包括 (a) 包含他沙西啶或其生理上可接受的酸加成盐的片芯；和 (b) 薄膜包衣、 其中薄膜包衣包裹片芯。
• Muscarinic M1 agonist as an inhibitor of beta-amyloid (ABeta40 and ABeta42)-synthesis
  申请人：——

  公开号：US20030050221A1

  公开（公告）日：2003-03-13

  A method of lowering the levels of A&bgr; 40 , A&bgr; 42 , and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine or a physiologically acceptable acid addition salt thereof and methods of treating or preventing diseases associated with the formation of diffuse and senile plaques or A&bgr; 40 -, A&bgr; 42 - and tau-containing plaques.

  降低 A&bgr； 40 , A&bgr； 42 和 tau 蛋白水平的方法，包括向哺乳动物施用有效量的他沙西啶或其生理上可接受的酸加成盐，以及治疗或预防与弥漫性和老年性斑块或 A&bgr； 40 -、A&bgr； 42 - 和含 tau 斑块相关疾病的治疗或预防方法。